The data are in the can, and this is a simpler study. Plus, as per the earlier missive from Stoll: "We also have paid the CRO an extra incentive fee to get their personnel to work overtime to get the job done more quickly."
My sense is that they may be dragging this out to get the press release after the dog-days of August. If they can get a bigger bounce out of the announcement, they can negotiate from a stronger position.
I don't at all mean to suggest that a positive outcome is a foregone conclusion. There are too many unknowns, and a resoundingly negative outcome (no efficacy, no analgesia preservation) may do this company in as surely as an RD-2 negative result would have. That said, I think that more is known about the mapping between rodents and humans in the domain of analgesia, so if Greer saw analgesia preservation in his rats, if the people carrying out this study know their stuff, they should be able to match analgesia levels (that's the hope anyway).
I'm also not saying that they are sitting on the results. I just think that they might see it to their advantage to drag the process out a bit, and my sense is that this is something that they can probably do.
News 
Market Data 
Discover 
AI
